Home » Topics » BioWorld Science

BioWorld Science
RSS

Adverum discontinues development of ADVM-043, advances ADVM-022

Nov. 2, 2018

Bavarian Nordic begins phase II dosing with BN-Brachyury in chordoma

Nov. 2, 2018

BioSpecifics reports topline phase I data for CCH in uterine fibroids

Nov. 2, 2018

European Commission approves Venclyxto with rituximab for relapsed/refractory CLL

Nov. 2, 2018

GlaxoSmithKline presents first-in-human data for GSK-3359609

Nov. 2, 2018

ViiV Healthcare presents positive results from the phase III BRIGHTE study of fostemsavir

Nov. 2, 2018

Targeting IL1R signaling may abrogate obesity-induced colon cancer

Nov. 2, 2018

Topline results reported from CLARITY phase II study of pimavanserin for MDD

Nov. 2, 2018

PAR and Parkinson's

Nov. 2, 2018

Daiichi Sankyo discontinues development of intradermal seasonal influenza vaccine

Nov. 2, 2018

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 7, 2026.
CINP 2026: Prenatal and adolescent stress shape brain vulnerability
BioWorld Science
Human biology is extraordinarily complex, and that sophistication emerges from the very beginning. During embryonic and fetal development, the organism’s...
Hyperexcitability may be joint problem in epilepsy, dementia
BioWorld
The majority of epilepsies are developmental disorders that start in childhood. But there is a large minority that starts in late adulthood. And increasingly,...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
In the clinic for July 6, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: Arcus, Genentech, Merck, Myriad, Otsuka, Partner, Revolution, Treos.